Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoCART: Neoadjuvant Docetaxel + Carboplatin vs EC-D in TNBC
NCT03154749Phase 2Completed
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Sep 2016
- Primary completion
- Dec 2019
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of carboplatin in triple-negative breast cancer (TNBC) (2 arms), sponsored by Guangdong Provincial People's Hospital. Primary endpoint: Pathologic Complete Response. Started Sep 2016; status: completed.
02
Drugs
carboplatin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03154749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03154749.